A new study suggests that high-dose palliative radiation therapy can be an effective and tolerable option for patients with incurable mucosal head and neck squamous cell carcinoma (HNSCC) who are not candidates for standard chemoradiotherapy.
In the study, 92.4% of patients completed the full radiation course of 50–55 Gy delivered over four weeks. At 12 months, 80% of patients achieved control of the tumor within the treated area. The median overall survival was 1.8 years, and 60% of patients were alive at one year.
Outcomes were worse for patients with larger tumors (T3 or T4), more advanced disease (Stage III or IV), and for those who were current smokers, who had higher rates of treatment failure.
The treatment was generally well tolerated. Severe (Grade 3) side effects occurred in 28% of patients, most commonly mucositis, pain, and difficulty swallowing. More than 90% of patients had recovered from treatment-related side effects six months after therapy. There were no life-threatening (Grade 4) toxicities or treatment-related deaths reported.
There is currently no global agreement on the best palliative radiation dose for HNSCC. This study provides real-world evidence that a 20-fraction, high-dose regimen can offer meaningful tumor control for nearly two years while maintaining acceptable quality of life in patients who are not eligible for curative treatment.